ARID1A is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CYSLTR2 is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CYSLTR2 status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GNA11 is an inclusion eligibility criterion in 2 clinical trials for uveal melanoma, of which 2 are open and 0 are closed. Of the trials that contain GNA11 status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

GNAQ is an inclusion eligibility criterion in 2 clinical trials for uveal melanoma, of which 2 are open and 0 are closed. Of the trials that contain GNAQ status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PLCB4 is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PLCB4 status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PRKCA is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCA status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCB is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCB status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCD is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCD status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCE is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCE status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCG is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCG status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCI is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCI status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCQ is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCQ status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCZ is an inclusion eligibility criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCZ status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].